

Currently released so far... 51122 / 251,287
Articles
Brazil
Sri Lanka
United Kingdom
Sweden
00. Editorial
United States
Latin America
Egypt
Jordan
Yemen
Thailand
Browse latest releases
2010/12/01
2010/12/02
2010/12/03
2010/12/04
2010/12/05
2010/12/06
2010/12/07
2010/12/08
2010/12/09
2010/12/10
2010/12/11
2010/12/12
2010/12/13
2010/12/14
2010/12/15
2010/12/16
2010/12/17
2010/12/18
2010/12/19
2010/12/20
2010/12/21
2010/12/22
2010/12/23
2010/12/24
2010/12/25
2010/12/26
2010/12/27
2010/12/28
2010/12/29
2010/12/30
2011/01/01
2011/01/02
2011/01/04
2011/01/05
2011/01/07
2011/01/09
2011/01/11
2011/01/12
2011/01/13
2011/01/14
2011/01/15
2011/01/16
2011/01/17
2011/01/18
2011/01/19
2011/01/20
2011/01/21
2011/01/22
2011/01/23
2011/01/24
2011/01/25
2011/01/26
2011/01/27
2011/01/28
2011/01/29
2011/01/30
2011/01/31
2011/02/01
2011/02/02
2011/02/03
2011/02/04
2011/02/05
2011/02/06
2011/02/07
2011/02/08
2011/02/09
2011/02/10
2011/02/11
2011/02/12
2011/02/13
2011/02/14
2011/02/15
2011/02/16
2011/02/17
2011/02/18
2011/02/19
2011/02/20
2011/02/21
2011/02/22
2011/02/23
2011/02/24
2011/02/25
2011/02/26
2011/02/27
2011/02/28
2011/03/01
2011/03/02
2011/03/03
2011/03/04
2011/03/05
2011/03/06
2011/03/07
2011/03/08
2011/03/09
2011/03/10
2011/03/11
2011/03/13
2011/03/14
2011/03/15
2011/03/16
2011/03/17
2011/03/18
2011/03/19
2011/03/20
2011/03/21
2011/03/22
2011/03/23
2011/03/24
2011/03/25
2011/03/26
2011/03/27
2011/03/28
2011/03/29
2011/03/30
2011/03/31
2011/04/01
2011/04/02
2011/04/03
2011/04/04
2011/04/05
2011/04/06
2011/04/07
2011/04/08
2011/04/09
2011/04/10
2011/04/11
2011/04/12
2011/04/13
2011/04/14
2011/04/15
2011/04/16
2011/04/17
2011/04/18
2011/04/19
2011/04/20
2011/04/21
2011/04/22
2011/04/23
2011/04/24
2011/04/25
2011/04/26
2011/04/27
2011/04/28
2011/04/29
2011/04/30
2011/05/01
2011/05/02
2011/05/03
2011/05/04
2011/05/05
2011/05/06
2011/05/07
2011/05/08
2011/05/09
2011/05/10
2011/05/11
2011/05/12
2011/05/13
2011/05/14
2011/05/15
2011/05/16
2011/05/17
2011/05/18
2011/05/19
2011/05/20
2011/05/21
2011/05/22
2011/05/23
2011/05/24
2011/05/25
2011/05/26
2011/05/27
2011/05/28
2011/05/29
2011/05/30
2011/05/31
2011/06/01
2011/06/02
2011/06/03
2011/06/04
2011/06/05
2011/06/06
2011/06/07
2011/06/08
2011/06/09
2011/06/10
2011/06/11
2011/06/12
2011/06/13
2011/06/14
2011/06/15
2011/06/16
2011/06/17
2011/06/18
2011/06/19
2011/06/20
2011/06/21
2011/06/22
2011/06/23
2011/06/24
2011/06/25
2011/06/26
2011/06/27
2011/06/28
2011/06/29
2011/06/30
2011/07/01
2011/07/02
2011/07/04
2011/07/05
2011/07/06
2011/07/07
2011/07/08
2011/07/10
2011/07/11
2011/07/12
2011/07/13
2011/07/14
2011/07/15
2011/07/16
2011/07/17
2011/07/18
2011/07/19
2011/07/20
2011/07/21
2011/07/22
2011/07/23
2011/07/25
2011/07/27
2011/07/28
2011/07/29
2011/07/31
2011/08/01
2011/08/02
2011/08/03
2011/08/05
2011/08/06
2011/08/07
2011/08/08
2011/08/09
2011/08/10
2011/08/11
2011/08/12
2011/08/13
2011/08/15
2011/08/16
2011/08/17
2011/08/18
2011/08/19
2011/08/21
2011/08/22
2011/08/23
2011/08/24
Browse by creation date
Browse by origin
Embassy Athens
Embassy Asuncion
Embassy Astana
Embassy Asmara
Embassy Ashgabat
Embassy Apia
Embassy Antananarivo
Embassy Ankara
Embassy Amman
Embassy Algiers
Embassy Addis Ababa
Embassy Accra
Embassy Abuja
Embassy Abu Dhabi
Embassy Abidjan
Consulate Auckland
Consulate Amsterdam
Consulate Alexandria
Consulate Adana
American Institute Taiwan, Taipei
Embasy Bonn
Embassy Bujumbura
Embassy Buenos Aires
Embassy Budapest
Embassy Bucharest
Embassy Brussels
Embassy Bridgetown
Embassy Brazzaville
Embassy Bratislava
Embassy Brasilia
Embassy Bogota
Embassy Bishkek
Embassy Bern
Embassy Berlin
Embassy Belmopan
Embassy Belgrade
Embassy Beirut
Embassy Beijing
Embassy Banjul
Embassy Bangui
Embassy Bangkok
Embassy Bandar Seri Begawan
Embassy Bamako
Embassy Baku
Embassy Baghdad
Consulate Belfast
Consulate Barcelona
Embassy Cotonou
Embassy Copenhagen
Embassy Conakry
Embassy Colombo
Embassy Chisinau
Embassy Caracas
Embassy Canberra
Embassy Cairo
Consulate Curacao
Consulate Ciudad Juarez
Consulate Chiang Mai
Consulate Chennai
Consulate Chengdu
Consulate Casablanca
Consulate Cape Town
Consulate Calgary
Embassy Dushanbe
Embassy Dublin
Embassy Doha
Embassy Djibouti
Embassy Dili
Embassy Dhaka
Embassy Dar Es Salaam
Embassy Damascus
Embassy Dakar
DIR FSINFATC
Consulate Dusseldorf
Consulate Durban
Consulate Dubai
Consulate Dhahran
Embassy Guatemala
Embassy Grenada
Embassy Georgetown
Embassy Gaborone
Consulate Guayaquil
Consulate Guangzhou
Consulate Guadalajara
Embassy Helsinki
Embassy Harare
Embassy Hanoi
Consulate Hong Kong
Consulate Ho Chi Minh City
Consulate Hermosillo
Consulate Hamilton
Consulate Hamburg
Consulate Halifax
Embassy Kyiv
Embassy Kuwait
Embassy Kuala Lumpur
Embassy Kolonia
Embassy Kinshasa
Embassy Kingston
Embassy Kigali
Embassy Khartoum
Embassy Kathmandu
Embassy Kampala
Embassy Kabul
Consulate Krakow
Consulate Kolkata
Consulate Karachi
Embassy Luxembourg
Embassy Lusaka
Embassy Luanda
Embassy London
Embassy Lome
Embassy Ljubljana
Embassy Lisbon
Embassy Lima
Embassy Lilongwe
Embassy Libreville
Embassy La Paz
Consulate Leipzig
Consulate Lahore
Consulate Lagos
Mission USOSCE
Mission USNATO
Mission UNESCO
Mission Geneva
Embassy Muscat
Embassy Moscow
Embassy Montevideo
Embassy Monrovia
Embassy Mogadishu
Embassy Minsk
Embassy Mexico
Embassy Mbabane
Embassy Maseru
Embassy Maputo
Embassy Manila
Embassy Manama
Embassy Managua
Embassy Malabo
Embassy Madrid
Consulate Munich
Consulate Mumbai
Consulate Montreal
Consulate Monterrey
Consulate Milan
Consulate Merida
Consulate Melbourne
Consulate Matamoros
Consulate Marseille
Embassy Nouakchott
Embassy Nicosia
Embassy Niamey
Embassy New Delhi
Embassy Ndjamena
Embassy Nassau
Embassy Nairobi
Consulate Nuevo Laredo
Consulate Naples
Consulate Naha
Consulate Nagoya
Embassy Pristina
Embassy Pretoria
Embassy Praia
Embassy Prague
Embassy Port Of Spain
Embassy Port Moresby
Embassy Port Louis
Embassy Port Au Prince
Embassy Podgorica
Embassy Phnom Penh
Embassy Paris
Embassy Paramaribo
Embassy Panama
Consulate Peshawar
REO Hillah
REO Basrah
Embassy Rome
Embassy Riyadh
Embassy Riga
Embassy Reykjavik
Embassy Rangoon
Embassy Rabat
Consulate Rio De Janeiro
Consulate Recife
Secretary of State
Embassy Suva
Embassy Stockholm
Embassy Sofia
Embassy Skopje
Embassy Singapore
Embassy Seoul
Embassy Sarajevo
Embassy Santo Domingo
Embassy Santiago
Embassy Sanaa
Embassy San Salvador
Embassy San Jose
Consulate Surabaya
Consulate Strasbourg
Consulate St Petersburg
Consulate Shenyang
Consulate Shanghai
Consulate Sapporo
Consulate Sao Paulo
Embassy Tunis
Embassy Tripoli
Embassy Tokyo
Embassy Tirana
Embassy The Hague
Embassy Tel Aviv
Embassy Tehran
Embassy Tegucigalpa
Embassy Tbilisi
Embassy Tashkent
Embassy Tallinn
Consulate Toronto
Consulate Tijuana
Consulate Thessaloniki
USUN New York
USMISSION USTR GENEVA
USEU Brussels
US Office Almaty
US Mission Geneva
US Mission CD Geneva
US Interests Section Havana
US Delegation, Secretary
UNVIE
UN Rome
Embassy Ulaanbaatar
Embassy Vilnius
Embassy Vientiane
Embassy Vienna
Embassy Vatican
Embassy Valletta
Consulate Vladivostok
Consulate Vancouver
Browse by tag
AMGT
ASEC
AEMR
AR
APECO
AU
AORC
ADANA
AJ
AF
AFIN
AMED
AS
AM
ABLD
AFFAIRS
AMB
APER
ACOA
AND
AA
AE
AADP
AID
AO
AL
AG
AORD
ADM
AINF
AINT
ASEAN
AORG
ABT
APEC
AY
ASUP
ARF
AGOA
AVIAN
ATRN
ANET
AGIT
ASECVE
ABUD
AODE
ALOW
ADB
AN
ADPM
ASPA
ARABL
AFSN
AZ
AC
AIAG
AFSI
ASCE
ASIG
ACABQ
ADIP
AFGHANISTAN
AROC
ADCO
ACOTA
ANARCHISTS
AMEDCASCKFLO
AK
ARABBL
ASCH
ANTITERRORISM
AGRICULTURE
AOCR
ARR
ASSEMBLY
AORCYM
AFPK
ACKM
AGMT
AEC
APRC
AIN
AFPREL
ASFC
ASECTH
AFSA
AINR
AOPC
AFAF
AFARI
AX
ASECAF
ASECAFIN
AT
AFZAL
APCS
AGAO
AIT
ARCH
AEMRASECCASCKFLOMARRPRELPINRAMGTJMXL
AMEX
ARM
AQ
ATFN
AMBASSADOR
AORCD
AVIATION
ARAS
AINFCY
ACBAQ
AOPR
AREP
AOIC
ASEX
ASEK
AER
AGR
AMCT
AVERY
APR
AEMRS
AFU
AMG
ATPDEA
ASECKFRDCVISKIRFPHUMSMIGEG
AORL
ACS
AMCHAMS
AECL
AUC
ACAO
BA
BR
BB
BG
BEXP
BY
BRUSSELS
BU
BD
BTIO
BK
BL
BE
BMGT
BO
BM
BX
BN
BWC
BBSR
BTT
BC
BH
BILAT
BUSH
BHUM
BT
BTC
BMENA
BOND
BAIO
BP
BF
BRPA
BURNS
BUT
BBG
BCW
BOEHNER
BOL
BASHAR
BIDEN
BFIN
BZ
BEXPC
BTIU
CPAS
CA
CASC
CS
CBW
CIDA
CO
CODEL
CI
CROS
CU
CH
CWC
CMGT
CVIS
CDG
CTR
CG
CF
CHIEF
CJAN
CBSA
CE
CY
CB
CW
CM
CHR
CD
COE
CV
COUNTER
CT
CN
CPUOS
CTERR
CVR
CVPR
CDC
COUNTRY
CLEARANCE
CONS
COM
CACS
CR
CONTROLS
CAN
CACM
COMMERCE
CAMBODIA
CFIS
COUNTERTERRORISM
CITES
CONDOLEEZZA
CZ
CTBT
CEN
CLINTON
CFED
CARC
CTM
CARICOM
CSW
CICTE
CYPRUS
CBE
CMGMT
CARSON
CWCM
CIVS
COUNTRYCLEARANCE
CENTCOM
CAPC
COPUOS
CKGR
CITEL
CQ
CITT
CIC
CARIB
CVIC
CAFTA
CVISU
CDB
CEDAW
CNC
CJUS
COMMAND
CENTER
COL
CAJC
CONSULAR
CLMT
CBC
CIA
CNARC
CIS
CEUDA
CHINA
CAC
CL
DR
DJ
DEMOCRATIC
DEMARCHE
DOMESTIC
DISENGAGEMENT
DB
DA
DHS
DAO
DCM
DAVID
DO
DEAX
DEFENSE
DEA
DTRO
DPRK
DOC
DTRA
DK
DAC
DOD
DRL
DRC
DCG
DE
DOT
DEPT
DOE
DS
DKEM
ECON
ETTC
EFIS
ETRD
EC
EMIN
EAGR
EAID
EFIN
EUN
ECIN
EG
EWWT
EINV
ENRG
ELAB
EPET
EIND
EN
EAIR
EUMEM
ECPS
ES
EI
ELTN
ET
EZ
EU
ER
EINT
ENGR
ECONOMIC
ENIV
EFTA
ETRN
EMS
EUREM
EPA
ESTH
EEB
EET
ENV
EAG
EXIM
ECTRD
ELNT
ENVIRONMENT
ECA
EAP
EINDIR
ETR
ECONOMY
ETRC
ELECTIONS
EICN
EXPORT
EARG
EGHG
EID
ETRO
EINF
EAIDHO
ECIP
EENV
EURM
EPEC
ERNG
ENERG
EIAD
EXBS
ED
EREL
ELAM
EK
EWT
ENGRD
EDEV
ECE
ENGY
EXIMOPIC
ETRDEC
ECCT
EUR
ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID
EFI
ECOSOC
EXTERNAL
ESCAP
ETCC
EENG
ERA
ENRD
ECLAC
ETRAD
EBRD
ENVR
ECONENRG
ELTNSNAR
ELAP
EPIT
EDUC
EAIDXMXAXBXFFR
EETC
EIVN
EDRC
EGOV
ETRA
EAIDRW
ETRDEINVECINPGOVCS
ESA
ETRDGK
ENVI
ELN
EPRT
EPTED
ERTD
EUM
EAIDS
EFINECONEAIDUNGAGM
EDU
EV
EAIDAF
EDA
EPREL
EINVEFIN
EAGER
ETMIN
EUCOM
ECCP
EIDN
EINVKSCA
ENNP
EFINECONCS
ETC
EAIRASECCASCID
EINN
ETRP
ECONOMICS
ENERGY
EIAR
EINDETRD
ECONEFIN
EURN
ETRDEINVTINTCS
EFIM
ETIO
EATO
EIPR
EINVETC
ETTD
ETDR
EIQ
ECONCS
ENRGIZ
EAIG
ENTG
EUC
ERD
EINVECONSENVCSJA
EEPET
EUNCH
ESENV
ECINECONCS
ETRDECONWTOCS
ECUN
FR
FI
FOREIGN
FARM
FIR
FAO
FK
FARC
FAS
FJ
FREEDOM
FAC
FINANCE
FBI
FTAA
FM
FCS
FAA
FORCE
FDA
FTA
FT
FCSC
FMGT
FINR
FIN
FDIC
FOR
FOI
FO
FMLN
FISO
GM
GERARD
GT
GA
GG
GR
GTIP
GH
GZ
GE
GB
GY
GAZA
GJ
GEORGE
GOI
GCC
GMUS
GI
GLOBAL
GV
GC
GL
GOV
GKGIC
GF
GWI
GIPNC
GUTIERREZ
GTMO
GANGS
GAERC
GUILLERMO
GASPAR
HR
HA
HYMPSK
HO
HK
HUMAN
HU
HN
HHS
HURI
HUD
HUMRIT
HUMANITARIAN
HUMANR
HL
HSTC
HILLARY
HCOPIL
HADLEY
HOURANI
HI
HUM
HEBRON
HUMOR
IZ
IN
IAEA
IS
IMO
ILO
IR
IC
IT
ITU
ID
IV
IMF
IBRD
IWC
ICAO
ICRC
INF
IO
IPR
ISO
IK
ISRAELI
IQ
ICES
IDB
INFLUENZA
IRAQI
ISCON
IGAD
IRAN
ITALY
IRAQ
ICTY
ICTR
ITPGOV
ITALIAN
IQNV
IADB
INTERNAL
INMARSAT
IRDB
ILC
INCB
INRB
ICJ
ISRAEL
INR
IEA
ISPA
ICCAT
IOM
ITRD
IHO
IL
IFAD
ITRA
IDLI
ISCA
INL
INRA
INTELSAT
ISAF
ISPL
IRS
IEF
ITER
INDO
IIP
IND
IEFIN
IACI
IAHRC
INNP
IA
INTERPOL
IFIN
ISSUES
IZPREL
IRAJ
IF
ITPHUM
ITA
IP
IRPE
IDA
ISLAMISTS
ITF
INRO
IBET
IDP
IRC
KMDR
KPAO
KOMC
KNNP
KFLO
KDEM
KSUM
KIPR
KFLU
KE
KCRM
KJUS
KAWC
KZ
KSCA
KDRG
KCOR
KGHG
KPAL
KTIP
KMCA
KCRS
KPKO
KOLY
KRVC
KVPR
KG
KWBG
KTER
KS
KN
KSPR
KWMN
KV
KTFN
KFRD
KU
KSTC
KSTH
KISL
KGIC
KSEP
KFIN
KTEX
KTIA
KUNR
KCMR
KCIP
KMOC
KTDB
KBIO
KBCT
KMPI
KSAF
KACT
KFEM
KPRV
KPWR
KIRC
KCFE
KRIM
KHIV
KHLS
KVIR
KNNNP
KCEM
KLIG
KIRF
KNUP
KSAC
KNUC
KPGOV
KTDD
KIDE
KOMS
KLFU
KNNC
KMFO
KSEO
KJRE
KJUST
KMRS
KSRE
KGIT
KPIR
KPOA
KUWAIT
KIVP
KICC
KSCS
KPOL
KSEAO
KRCM
KSCI
KNAP
KGLB
KICA
KCUL
KPRM
KFSC
KQ
KPOP
KPFO
KPALAOIS
KREC
KBWG
KR
KTTB
KNAR
KCOM
KESS
KINR
KOCI
KWN
KCSY
KREL
KTBT
KFTN
KW
KRFD
KFLOA
KHDP
KNEP
KIND
KHUM
KSKN
KOMO
KDRL
KTFIN
KSOC
KPO
KGIV
KSTCPL
KSI
KPRP
KFPC
KNNB
KNDP
KICCPUR
KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG
KDMR
KFCE
KIMMITT
KMCC
KMNP
KSEC
KOMCSG
KGCC
KRAD
KCRP
KAUST
KWAWC
KCHG
KRDP
KPAS
KTIAPARM
KPAOPREL
KWGB
KIRP
KMIG
KLAB
KSEI
KHSA
KNPP
KPAONZ
KWWW
KGHA
KY
KCRIM
KCRCM
KGCN
KPLS
KIIP
KPAOY
KTRD
KTAO
KJU
KBTS
KWAC
KFIU
KNNO
KPAI
KILS
KPA
KRCS
KWBGSY
KNPPIS
KNNPMNUC
KNPT
KERG
KLTN
KPREL
KTLA
KO
KAWK
KVRP
KAID
KX
KENV
KWCI
KNPR
KCFC
KNEI
KFTFN
KTFM
KCERS
KDEMAF
KMEPI
KEMS
KBTR
KEDU
KIRL
KNNR
KMPT
KPDD
KPIN
KDEV
KFRP
KTBD
KMSG
KWWMN
KWBC
KA
KOM
KWNM
KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG
KRGY
KNNF
KICR
KIFR
KWMNCS
KPAK
KDDG
KCGC
KID
KNSD
KMPF
KWMM
MARR
MX
MASS
MOPS
MNUC
MCAP
MTCRE
MRCRE
MTRE
MASC
MY
MK
MG
MU
MILI
MO
MZ
MEPP
MCC
MEDIA
MOPPS
MI
MAS
MW
MP
MEPN
MV
MD
MR
MC
MCA
MT
MIL
MARITIME
MOPSGRPARM
MAAR
MOOPS
ML
MA
MN
MNUCPTEREZ
MTCR
MUNC
MPOS
MONUC
MGMT
MURRAY
MACP
MINUSTAH
MCCONNELL
MGT
MNUR
MF
MEPI
MOHAMMAD
MAR
MAPP
MNU
MFA
MTS
MLS
MEETINGS
MERCOSUR
MED
MNVC
MIK
MBM
MILITARY
MAPS
MARAD
MDC
MACEDONIA
MASSMNUC
MUCN
MQADHAFI
MPS
NZ
NATO
NI
NO
NU
NG
NL
NPT
NS
NA
NP
NASA
NSF
NEA
NANCY
NSG
NRR
NATIONAL
NMNUC
NC
NSC
NAS
NARC
NELSON
NATEU
NDP
NIH
NK
NIPP
NR
NERG
NSSP
NE
NTDB
NT
NEGROPONTE
NGO
NATOIRAQ
NAR
NZUS
NCCC
NH
NAFTA
NEW
NRG
NUIN
NOVO
NATOPREL
NV
NICHOLAS
NPA
NSFO
NW
NORAD
NPG
NOAA
OPRC
OPDC
OTRA
OECD
OVIP
OREP
ODC
OIIP
OAS
OSCE
OPIC
OMS
OFDP
OFDA
OEXC
OPCW
OIE
OSCI
OM
OPAD
ODPC
OIC
ODIP
OPPI
ORA
OCEA
OREG
OMIG
OFFICIALS
OSAC
OEXP
OPEC
OFPD
OAU
OCII
OIL
OVIPPRELUNGANU
OSHA
OPCD
OPCR
OF
OFDPQIS
OSIC
OHUM
OTR
OBSP
OGAC
OESC
OVP
ON
OES
OTAR
OCS
PREL
PGOV
PARM
PINR
PHUM
PM
PREF
PTER
PK
PINS
PBIO
PHSA
PE
PBTS
PA
PL
POL
PAK
POV
POLITICS
POLICY
PO
PRELTBIOBA
PKO
PIN
PNAT
PU
PGOVPREL
PALESTINIAN
PTERPGOV
PELOSI
PAS
PP
PTEL
PROP
PRELAF
PRHUM
PRE
PUNE
PIRF
PVOV
PROG
PERSONS
PROV
PKK
PRGOV
PH
PLAB
PDEM
PCI
PRL
PRM
PINSO
PERM
PETR
PPAO
PERL
PBS
PETERS
PRELBR
PCON
POLITICAL
PMIL
POLM
PKPA
PNUM
PLO
PTERM
PJUS
PARMP
PNIR
PHUMKPAL
PG
PREZ
PGIC
PAO
PROTECTION
PRELPK
PGOVENRG
PATTY
PSOC
PARTIES
PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ
PMIG
PAIGH
PARK
PETER
PHUS
PKPO
PGOVECON
POUS
PMAR
PWBG
PAR
PGOVGM
PHUH
PTE
PY
POLUN
PDOV
PGOVSOCI
PGOVPM
PRELEVU
PGOR
PBTSRU
PHUMA
PHUMR
PPD
PGV
PRAM
PARMS
PINL
PSI
PKPAL
PPA
PTERE
PGOF
PINO
PREO
PHAS
PAC
PRESL
PORG
PS
PGVO
PKFK
PSOE
PEPR
PINT
PRELP
PREFA
PNG
PTBS
PFOR
PGOVLO
PHUMBA
PREK
PHJM
POLINT
PGOVE
PHALANAGE
PARTY
PECON
PEACE
PROCESS
PLN
PEDRO
PF
PGPV
PCUL
PGGV
PSA
PGOVSMIGKCRMKWMNPHUMCVISKFRDCA
PGIV
PHUMPREL
POGOV
PEL
PBT
PAMQ
PINF
PSEPC
POSTS
PAHO
PHUMPGOV
PGOC
PNR
RS
RP
RU
RW
RFE
RCMP
RIGHTSPOLMIL
REFORM
RO
ROW
ROBERT
REACTION
REPORT
REGION
RELATIONS
RAY
ROBERTG
RIGHTS
RM
RATIFICATION
RREL
RBI
RICE
ROOD
REL
RODHAM
RGY
RUEHZO
RELIGIOUS
RELFREE
RUEUN
RELAM
RSP
RF
REO
REGIONAL
RUPREL
RI
REMON
RPEL
RSO
SCUL
SENV
SOCI
SZ
SNAR
SO
SP
SU
SY
SI
SMIG
SYR
SA
SW
SF
SR
SYRIA
SNARM
START
SPECIALIST
SG
SNIG
SCI
SGWI
SE
SIPDIS
SANC
SELAB
SN
SETTLEMENTS
SCIENCE
SENVENV
SENS
SPCE
SPAS
SECURITY
SENC
SOCIETY
SOSI
SENVEAGREAIDTBIOECONSOCIXR
SEN
SPECI
ST
SL
SENVCASCEAIDID
SC
SECRETARY
STR
SNA
SOCIS
SADC
SEP
SK
SHUM
SYAI
SMIL
STEPHEN
SNRV
SKCA
SENSITIVE
SECI
SCUD
SCRM
SGNV
SECTOR
SAARC
SENVSXE
SWMN
STEINBERG
SOPN
SOCR
SCRS
SWE
SARS
SNARIZ
SUDAN
SENVQGR
SAN
SM
SFNV
SSA
SPCVIS
SOFA
SCULKPAOECONTU
SENVKGHG
SHI
SEVN
SH
SNARCS
SNARN
SIPRS
TBIO
TW
TRGY
TSPA
TU
TPHY
TI
TX
TH
TIP
TSPL
TNGD
TZ
TS
TC
TK
TURKEY
TERRORISM
TPSL
TINT
TRSY
TERFIN
TPP
TT
TECHNOLOGY
TE
TAGS
TRAFFICKING
TJ
TN
TO
TD
TP
TREATY
TR
TA
TIO
TECH
TF
TRAD
TNDG
TWI
TPSA
TWL
TAUSCHER
TRBY
TL
TV
THPY
TSPAM
TREL
TRT
TNAR
TFIN
TWCH
THOMMA
THOMAS
TERROR
TRY
TBID
UK
UNESCO
UNSC
UNGA
UN
US
UZ
USEU
UG
UP
UNAUS
UNMIK
USTR
UY
USUN
UNEP
UNDC
UV
UNPUOS
UNSCR
USAID
UNODC
UNRCR
UNHCR
UNDP
UNCRIME
UA
UNHRC
UNRWA
UNO
UNCND
UNCHR
USAU
UNICEF
USPS
UNOMIG
UNESCOSCULPRELPHUMKPALCUIRXFVEKV
UR
UNFICYP
UNCITRAL
UNAMA
UNVIE
USTDA
USNC
UNCSD
USCC
UNEF
UNGAPL
USSC
UNMIC
UNTAC
UNCLASSIFIED
USDA
UNCTAD
USGS
UNFPA
UNSE
USOAS
UE
UAE
UNCHS
UNDESCO
UNC
UNSCS
UKXG
UNGACG
UNHR
UNBRO
UNCHC
UNFCYP
UNIDROIT
WHTI
WIPO
WTRO
WHO
WTO
WMO
WFP
WEET
WS
WE
WA
WHA
WBG
WILLIAM
WI
WSIS
WCL
WEBZ
WZ
WW
WWBG
WMD
WWT
WMN
WWARD
WITH
WTRQ
WCO
WEU
WB
WBEG
Browse by classification
Community resources
courage is contagious
Viewing cable 09TAIPEI760, Taiwan Pharma: 6th PVS Underway, Big Pricing Reforms
If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:
- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #09TAIPEI760.
Reference ID | Created | Released | Classification | Origin |
---|---|---|---|---|
09TAIPEI760 | 2009-06-24 09:17 | 2011-08-23 00:00 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | American Institute Taiwan, Taipei |
VZCZCXRO7611
PP RUEHCN RUEHGH RUEHVC
DE RUEHIN #0760/01 1750917
ZNR UUUUU ZZH
P 240917Z JUN 09
FM AIT TAIPEI
TO RUEHC/SECSTATE WASHDC PRIORITY 1815
INFO RUEHOO/CHINA POSTS COLLECTIVE
RUEHHK/AMCONSUL HONG KONG 0690
UNCLAS SECTION 01 OF 04 TAIPEI 000760
STATE PLEASE PASS TO AIT/W AND EAP/RSP/TC
STATE PASS USTR/EALTBACH AND USTR/JRAGLAND
USDOC FOR 4430/ITA/MAC
SENSITIVE
SIPDIS
E.O. 12958: N/A
TAGS: ECON ETRD KIPR TW
SUBJECT: Taiwan Pharma: 6th PVS Underway, Big Pricing Reforms
Unlikely
REF: A) 2007 Taipei 2326; B) 2007 Taipei 2498; C) 2008 Taipei 950;
D) 2007 Taipei 2257; E) 2008 Taipei 572; F) 2007 Taipei 2551; G)
Taipei 73
Summary
-------
1.(SBU) The Taiwan Department of Health (DOH) Bureau of National
Health Insurance (BNHI) will announce the results of the sixth
price-volume survey (PVS) in July, and implement revised
reimbursement prices in September. BNHI is following through on a
Ma administration campaign promise to reform Taiwan's overall
Pharmaceutical Benefits Scheme (PBS), and will finalize PBS guidance
in July. Although original-drug manufacturers are unhappy with the
current draft PBS reform, industry has failed to agree on a detailed
counter-proposal.
¶2. (SBU) The Bureau of Pharmaceutical Affairs (BOPA) wants to speed
up drug-approval times by reducing documentation requirements, but
the proposed conditions for reduced documentation are insignificant,
and will likely be little-used by drug-makers. Neither separation
of dispensing and prescribing (SDP) nor patent linkage--two of
industry's long-standing goals for Taiwan--have the support of
Taiwan industry or bureaucracy, though a newly-established Taiwan
Food and Drug Administration (TFDA) may make implementing
patent-linkage in Taiwan more feasible. BNHI continues to press
industry and AIT to support LY passage of a draft law requiring
hospitals to use a standard drug-purchasing contract. End summary.
Pricing Background
------------------
¶3. (SBU) Taiwan implemented a National Health Insurance (NHI) system
in 1995, and its health-care system comprises six large public
medical centers, 16 large privately-owned medical centers, and 417
regional and district hospitals. The 22 large medical centers
dominate the pharmaceutical market, and are able to negotiate very
low drug prices. Hospitals derive up to half of these revenues from
the difference between the lower prices they have negotiated with
drug companies and the higher amounts that BNHI reimburses for the
same drugs--the source of the so-called "Black Hole" in Taiwan's
pharmaceuticals budget. BNHI, in turn, uses biannual price-volume
surveys (PVS) to collect price data from hospitals and drug makers
to use in calculating new, lower drug reimbursements.
6th PVS Underway, Big Pricing Reform Unlikely
---------------------------------------------
¶4. (SBU) Taiwan law requires hospitals that accept reimbursements
from BNHI to provide price data for all pharmaceutical purchases.
Foreign original-drug manufacturers, however, initially refused to
supply pricing data in protest over past PVS methodology. After a
pause in the PVS process to allow BNHI to collect views from
industry, hospitals, and other stakeholders on reforming Taiwan's
Pharmaceutical Benefits Scheme (PBS)--including hosting a December
2008 industry-wide conference--in February, BNHI again requested
that companies submit pricing data.
¶5. (SBU) Lawyers for the foreign drug-makers' industry group in
Taiwan, the International Research-based Pharmaceutical Manufactures
Association (IRPMA), think BNHI does not have legal grounds to
compel companies to submit price data. However, both IRPMA and
AmCham Pharmaceutical Committee leaders asked member companies to do
so as a show of industry's good will, and in March, all member
companies submitted price data to BNHI. According to BNHI Vice
President Lee Cheng-hua, the new reimbursement prices will go into
effect on September 1.
¶6. (SBU) Foreign original-drug manufacturers fear the sixth PVS,
like the five before it, will significantly reduce reimbursements
for their drugs, as well as start another round of price-cut demands
from the large hospital groups. Foreign firms, however, have been
unable to reach consensus on how to respond concretely to BNHI's PVS
methodology. They will discuss instead their ideas on reforming the
overall PBS, and their plans to commission an economic model on
pharma pricing reform in Taiwan.
PBS Reform Request Backfires
----------------------------
7.(U) In response to a Ma campaign promise to reform Taiwan's
overall Pharmaceutical Benefits Scheme (PBS) and resolve the price
TAIPEI 00000760 002 OF 004
gap problem, BNHI hosted a one-day drug-pricing conference on
December 31, 2008. Representatives from all eight major drug
industry groups plus AmCham attended the conference, which produced
a PBS reform outline now under study by BNHI.
¶8. (SBU) Over the following months, however, BNHI made no moves to
implement the proposed changes. In May, IRPMA sent a petition to
DPP Legislator and former DOH Minister Twu Shiing-zher requesting
Twu push BNHI to move forward on PBS reform. Soon afterwards, Twu
asked DOH Deputy Minister Cheng Shou-hsia to work with industry to
finalize within three months a benefit scheme reform proposal, and,
in late May, the Legislative Yuan (LY) Health and Environment
Committee passed a Twu-backed non-binding resolution calling for the
same.
¶9. (SBU) In response to the LY pressure, BNHI notified industry in
May that the Bureau plans to produce a final PBS reform plan in
July, and asked for industry's input on the current draft plan.
However, despite a series of industry-BNHI meetings over the past
month, U.S. and other original-drug makers have failed to reach
consensus on industry's PBS reform counter-proposal. On June 5,
BNHI again informed AmCham and PhRMA representatives that the Bureau
will finalize the plan by mid-July, with or without industry input.
Proposed CPP Changes Not an Improvement
---------------------------------------
¶10. (U) A Certificate of Pharmaceutical Product (CPP) is a document
provided either directly by the manufacturer or by the release
country to attest that a drug has been approved for use in the
release country, has been manufactured in compliance with food and
drug safety in that country, and is labeled in the same manner as in
the original country. In most cases, drug manufacturers will supply
a CPP from a developed economy such as the United States or European
Union market to the drug-approval authorities in a second market in
order to demonstrate the drug is already for sale in another market,
and thereby reduce the time and paperwork needed to gain approval
for sale in the second market.
¶11. (U) When a pharmaceutical company applies for regulatory
approval to market a drug in a country, the authorities in that
country typically ask manufacturers to supply one CPP as proof that
the drug is approved for sale in another market. Taiwan, however,
requires CPPs from two countries. The two-CPP requirement
disadvantages U.S. firms because BOPA regards a CPP from the
European Union as the equivalent of multiple CPPs, while the same
document from the United States counts only as one CPP. In
addition, although CPPs from all countries follow a standard,
WHO-approved format, Taiwan requires notarization of CPPs by the
Taiwan representative office in the CPP-issuing country.
¶12. (U) For the past two years, original-drug manufactures have been
urging the DOH Bureau of Pharmaceutical Affairs (BOPA) to reduce the
required number of CPPs to one in order to shorten the drug-approval
process. In response, BOPA recently announced plans to reduce the
number of required CPPs from two to one if the manufacturer conducts
two phases of clinical trials in Taiwan for the drug in question.
[Note: Pharmaceutical companies conduct clinical trials to gather
data on the safety and efficacy of new drugs or new indications for
old drugs. Typically, three phases are needed before a country's
drug authorities will grant approval, with each successive phase
including a larger group of subjects. End note.]
¶13. (SBU) The deadline to submit public comments on the proposed
changes was June 8. BOPA's Dr. Liao told econoff on June 5 that
since the CPP requirement is an administrative guideline and not a
law, once DOH decides on the final rule change, BOPA will be able to
post the requirement within two weeks.
¶14. (SBU) However, local general managers of American drug companies
tell us that because Taiwan is a relatively small market, companies
are unlikely to conduct extra trials in Taiwan just to take
advantage of the reduced CPP requirement. Instead, the companies
will simply wait for a second country to issue a CPP for the drug
and then apply for Taiwan approval. In addition, because BOPA's
plan would increase the required number of trial subjects for some
of the phases, the change will often make doing clinical trials in
Taiwan less attractive.
¶15. (SBU) IRPMA member companies instead propose relaxing the
requirement to one CPP if the company performs one phase of trials
in Taiwan, or waiving the CPP requirement completely if a company
conducts two clinical trials in Taiwan. On June 5, econoff discussed
these alternatives with Dr. Liao, who agreed the latter change would
be more attractive for companies, and urged manufacturers to take
TAIPEI 00000760 003 OF 004
advantage of the public comment period to submit their ideas.
Still Little Support for SDP
----------------------------
¶16. (SBU) Currently, when a patient sees a doctor in a Taiwan
hospital, the patient will almost always fill his prescription at
the pharmacy owned by and located in the hospital. Because Taiwan's
hospitals get much of their revenues from the difference between the
lower prices they have negotiated with drug companies and the higher
amounts that BNHI reimburses for the same drugs (ref A), hospital
administrators and doctors have an incentive to both over-prescribe
and push down contract prices for drugs. Separating dispensing and
prescribing (SDP) would eliminate this incentive.
¶17. (SBU) The U.S. and Taiwan discuss SDP under the bilateral Trade
and Investment Framework Agreement (TIFA), and Taiwan has done some
small-scale SDP pilot programs. However, Taiwan's powerful
hospitals and doctors' associations do not support any move toward
SDP because it would sap hospitals' revenues. During a recent
AIT-hosted roundtable on SDP, hospital administrators and doctors
again objected loudly to any such moves, and BOPA is not actively
planning larger SDP initiatives. Any progress toward SDP will
require continued high-level engagement with the Taiwan
authorities.
Bureaucracy Opposes Patent Linkage
----------------------------------
¶18. (SBU) Taiwan lacks a patent-linkage notification requirement and
allows generic-drug licensing before patent expiry, practices that
foreign pharmaceutical manufacturers claim allow local generic drug
makers to infringe on patent-holders' rights, as well as secure a
higher initial reimbursement price from BNHI (ref B).
¶19. (SBU) The U.S. and the Taipei American Chamber of Commerce have
pushed the Taiwan authorities to implement a U.S.-style
patent-linkage system that would continue to allow generic-drug
testing before the original drug's patent expiration, but would
include protections for the patent-holder's IPR and prevent
generic-drug makers from licensing a generic form of a patented drug
while the original patent is still valid.
¶20. (SBU) The Taiwan pharmaceutical authorities, however, do not
want to implement a U.S.-style patent linkage system. On June 5,
BOPA Director General Chi-chou Liao reiterated to econoff that BOPA
does not think Taiwan needs to introduce patent linkage, since
Taiwan's court system, including the specialized Intellectual
Property (IP) Court (ref C) can efficiently resolve such IPR
disputes. As evidence, Liao pointed to a recent case in which
Pfizer sued several local firms for releasing generic versions of
Pfizer's Lipitor prior before the original drug's patent expired.
Although Pfizer lost, Liao said the case shows the specialized court
can effectively handle drug-related IPR disputes.
BNHI Wants Industry, U.S. Support for Mandatory SC
--------------------------------------------- -----
¶21. (SBU) In response to U.S. concerns about the lack of
transparency in drug procurement by Taiwan hospitals, during the
2007 TIFA meetings in Washington, Taiwan committed to implementing a
mandatory standard contract (SC) that would require all hospitals to
use the same contract for all drug purchases (ref D).
¶22. (SBU) In September 2007, the Taiwan Executive Yuan(EY) forwarded
to the Legislative Yuan (LY) draft legislation that would require
hospitals to use an SC for pharmaceutical purchases. If the law
passes, BNHI would then finalize the text of the contract by
administrative order. The current draft SC would require full
disclosure of the actual price and allow the Bureau of National
Health Insurance (BNHI) to more accurately establish real
transaction prices in their price surveys.
¶23. (SBU) According to IRPMA Chief Operating Officer Carol Cheng,
hospitals do not support the current BNHI draft SC because it would
bring more transparency to their current pricing practices,
potentially reducing the pricing gap that funds their operations.
Foreign original-drug manufacturers also object to the proposed SC
language, which would codify a practice whereby hospitals
automatically renegotiate price contracts with drug companies
whenever BNHI announces new, lower prices.
¶24. (SBU) Without industry or hospital support, the draft
TAIPEI 00000760 004 OF 004
legislation authorizing SC has languished in the LY since 2007.
Acting BNHI President Lee has repeatedly asked IRPMA and member
companies, as well as AIT, to lobby the LY for the proposed changes.
Comment
-------
¶25. (SBU) Because Taiwan has no major new-drug makers, hospitals
that rely heavily on profits from BNHI drug reimbursements, and
consumers who are largely satisfied with the current system, there
is limited domestic support for reforming pricing practices. In
addition, with an economy in the doldrums and the national health
care system at least USD two billion in the red (ref E), financial
pressures will undercut any near-term move to spend more on
reimbursement for on-patent drugs, or increase hospital funding in
conjunction with implementing SDP.
¶26. (SBU) Therefore, the U.S.' pharma priority in Taiwan should be
support for low-cost reforms such as passing the draft standard
contract (SC) legislation and implementing patent linkage. While
U.S. industry dislikes BNHI's current SC language, the U.S. should
support passage of the bill authorizing BNHI to require that
hospitals use SCs, while working with industry and the authorities
to improve the draft SC language. Because SC is one of two
pharma-related TIFA topics, supporting SC plans could create
momentum within BNHI for addressing other pharma issues under the
TIFA rubric. In addition, although the Taiwan health bureaucracy
does not favor implementing patent linkage, the upcoming merger of
the DOH Bureau of Food Safety, Bureau of Pharmaceutical Affairs,
Bureau of Food and Drug analysis, and the National Bureau of
Controlled drugs into the Taiwan Food and Drug Administration (TFDA)
offers a chance for fresh engagement with new TFDA leadership.
¶27. (SBU) In the longer term, the U.S. should encourage Taiwan to
foster the policies and environment needed to commercialize Taiwan's
nascent biotech and biomedical industries. The authorities have
long identified biotech as a future strength of the Taiwan economy
(refs F and G), and an indigenous biotech industry developing
innovative drugs could kindle Taiwan interest in positive
pharmaceutical pricing and IP reforms. End comment.
YOUNG